Jul 23, 2026 04:00PM
Jul 23, 2026 04:00PM
Jul 13, 2026 06:36AM
Jul 2, 2026 06:41AM
Jun 11, 2026 10:46AM
Jun 11, 2026 10:45AM
Feb 23, 2026 06:28AM Genmab A/S (GMAB) PT Lowered to $40 at Guggenheim
Feb 17, 2026 11:01AM
Jan 28, 2026 06:42AM
Jan 20, 2026 06:39AM
Dec 8, 2025 04:15AM
Dec 7, 2025 07:50AM
Dec 7, 2025 07:50AM
Dec 7, 2025 07:50AM Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relaps
Dec 7, 2025 07:50AM
Nov 18, 2025 11:30AM
Nov 18, 2025 11:30AM
Nov 10, 2025 06:48AM
Nov 6, 2025 11:02AM
Nov 3, 2025 09:05AM
Oct 18, 2025 06:00AM Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Sep 29, 2025 01:08AM
Sep 29, 2025 01:08AM
Sep 3, 2025 08:30AM
Sep 3, 2025 08:30AM
Aug 19, 2025 08:01AM
Aug 19, 2025 08:00AM
Aug 15, 2025 06:51AM Genmab A/S (GMAB) PT Raised to $36 at H.C. Wainwright
Aug 7, 2025 11:08AM
Aug 7, 2025 10:30AM
Aug 7, 2025 10:30AM
Aug 7, 2025 10:30AM
Aug 7, 2025 10:30AM
May 1, 2025 08:24PM
May 1, 2025 08:14PM Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follic
Mar 17, 2025 12:19PM
Mar 17, 2025 12:19PM
Feb 12, 2025 11:01AM
Dec 21, 2024 10:00AM
Dec 7, 2024 07:00PM
Sep 20, 2024 06:48AM
Sep 15, 2024 08:45AM Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Aug 8, 2024 11:03AM
Jun 27, 2024 06:37AM
Jun 27, 2024 05:08AM
Jun 26, 2024 07:03PM
May 23, 2024 05:00PM
May 21, 2024 11:07AM
May 21, 2024 11:06AM Genmab Completes Acquisition of ProfoundBio
May 2, 2024 11:01AM

326,461 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All